Merck acquired Israeli immuno-oncology biotech cCAM Biotherapeutics for $95M upfront plus up to $510M in milestones, gaining anti-CEACAM1 antibody CM-24, then in Phase 1 evaluation in advanced solid tumors and hematologic malignancies.
Did it work? Outcome assessment
Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
Pipeline outcome
Assets Terminated
Assessment window: 10yr post-close.
Key facts
AnnouncedJul 31, 2015
ClosedAug 25, 2015
Deal value$605M
Deal typeAcquisition/Merger
Therapeutic areaAdvanced or recurrent malignancies (immuno-oncology)
IndicationsAdvanced or recurrent malignancies (immuno-oncology)